News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PURE Bioscience (PURE) Release: PURE Control Antimicrobial Listed As Safe And Suitable Ingredient In The USDA-FSIS Directive 7120.1 For Poultry Products



8/23/2017 7:20:14 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Commercialization Underway – Poultry Processors Preparing to Initiate In-Plant Validation for Poultry Parts Processing

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that PURE Control® antimicrobial is included in the newly updated list of Safe and Suitable Ingredients Used in Production of Meat, Poultry and Egg Products in the Food Safety and Inspection Service (FSIS) 7120.1 Directive (https://www.fsis.usda.gov/wps/wcm/connect/bab10e09-aefa-483b-8be8-809a1f051d4c/7120.1.pdf?MOD=AJPERES).

PURE has commenced commercialization of PURE Control to poultry processors, and two major processors are preparing to initiate their own in-plant validation work with FDA/USDA approved PURE Control to reduce Salmonella, Campylobacter and other pathogens to prevent foodborne illness.

Poultry Processing Market

  • Approximately 80% of all poultry processed is packaged for sale as parts (not whole birds).
  • The processing industry estimates that 65-75% of all poultry processing aids used are applied during pre- and post OLR (Online Reprocessing).
  • PURE has targeted +10% (+$35 million) annual market share of the $350 million total US market. US poultry processing plants each spend approx. +$1 million annually in processing aids and intervention chemistries. PURE Control is being marketed to replace the less effective and toxic chemicals presently used during reprocessing and in other intervention steps

Hank R. Lambert, CEO of PURE, said, “This FSIS Directive listing is a major step forward for PURE. The production of poultry parts is the largest portion of the processing aids market. The fact that several processors are already preparing to initiate in-plant validation of PURE Control is a strong indication of the demand for a more effective and safer product for microbial reduction. Upon successful completion of their respective in-plant work, we expect these processors will become our first poultry customers for PURE Control. We know of no other equally effective, non-toxic solution – and believe PURE Control is the breakthrough solution the poultry industry needs and has been waiting for.”

Given the importance of food safety, it is industry practice for customers of new food safety solutions like PURE Control to complete comprehensive internal validations prior to implementation. PURE welcomes and supports on-site customer trials with its technical support team.

Benefits of PURE Control

  • The effectiveness of PURE Control addresses the top priority of the USDA in its Salmonella Action Plan, to reduce the presence of Salmonella in poultry sold to consumers by 50% from current levels.
    • Presently approximately 28% of raw poultry sold to consumers contains Salmonella. Recently, a disturbing 40% of processors exceeded the maximum allowable percent positive of those pathogens during a three-month period.
  • While current toxic interventions can have a negative impact on yield, PURE Control has shown a neutral to positive processing yield impact.
  • Uniquely effective, SDC also mitigates bacterial resistance, which is a problematic issue with other commonly used chemistries.

Ongoing USDA Testing for Poultry OLR Use

PURE continues its ongoing in-plant raw poultry processing trial in which PURE Control is applied through a spray cabinet to whole chicken carcasses during Online Reprocessing (OLR), and is expected to complete that work by mid-calendar Q4.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; the Company’s ability to raise funds necessary to support its continued operations and the implementation of its business plan; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2016, second quarter ended January 31, 2017, and third quarter ended April 30, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts

PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
hlambert@purebio.com
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
terri@bibimac.com
or
Redwood Investment Group
Tom Hemingway
714-978-4425
tomh@redwoodfin.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES